Physician profile
Jeff Wang
NPI 1235121625
$5,491.26
in general payments reported to CMS, 2019-2025
28 companies · $783 in 2025
The $783 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $458 · 2020: $615 · 2021: $579 · 2022: $766 · 2023: $1,033 · 2024: $1,258 · 2025: $783.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,074.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,073.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,687.44 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $894.40 | 2019-2025 | Airsupra, Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $588.05 | 2024-2025 | |
| Lilly USA, LLC | $481.13 | 2020-2024 | Mounjaro, Jardiance, Zepbound |
| Abbott Laboratories | $296.79 | 2021-2023 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $226.99 | 2019-2023 | Jardiance |
| Boston Scientific Corporation | $219.44 | 2019-2024 | Therasphere Y90 Glass Microspheres 7.0 Gbq (US Commercial) |
| Amarin Pharma, INC. | $200.25 | 2020-2021 | |
| Idorsia Pharmaceuticals US INC | $149.31 | 2023 | Quviviq |
| Sanofi-Aventis U.S. LLC | $121.86 | 2024 | |
| Choice Spine, LLC | $101.12 | 2019 | |
| Glaxosmithkline, LLC. | $54.42 | 2023-2024 | Arexvy, Shingrix |
| Astellas Pharma US INC | $47.80 | 2024-2025 | Veozah |
| Amgen INC. | $46.53 | 2023-2024 | Repatha, Otezla |
| Seqirus USA INC | $40.74 | 2023-2024 | Flucelvax, Fluad, Flucelvax Quadrivalent |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $36.56 | 2024 | Spravato |
| Imperative Care, INC | $34.85 | 2024 | Hotshot Controller |
| Therapeuticsmd, INC. | $34.85 | 2019-2020 | |
| Eisai INC. | $32.47 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $30.71 | 2023 | Seglentis |
| Genentech USA, INC. | $30.69 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $28.97 | 2019-2020 | |
| Myocardial Solutions, INC. | $22.90 | 2021 | |
| Shield Therapeutics INC | $19.49 | 2024 | |
| Exact Sciences Corporation | $18.93 | 2025 | Cologuard Collection Kit |
| Xeris Pharmaceuticals, INC. | $16.33 | 2023 | Gvoke Hypopen |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.87 | 2025 | Xifaxan |
| Vertical Pharmaceuticals, LLC | $13.37 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeff Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.